Immune responses in neurodegenerative diseases

Kathmandu University Medical Journal

Volumn 12, Issue 45, 2014, Pages 67-76

  Shrestha, Rajeev ^a   Shakya Shrestha, S ^a   Millington, O ^b   Brewer, J ^c   Bushell, T ^b  

^a KATHMANDU UNIVERSITY SCHOOL OF MEDICAL SCIENCES   (Nepal)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Alzheimer s disease; Lymphocytes; Multiple sclerosis; Neurodegenerative diseases; Parkinson s disease; Stroke; T cells

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; B LYMPHOCYTE; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; T LYMPHOCYTE; DISEASE COURSE; FEMALE; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; PATHOPHYSIOLOGY; STROKE;

ALZHEIMER DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; MACROPHAGES; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STROKE; T-LYMPHOCYTES;

EID: 84908025361     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v12i1.13646     Document Type: Article

References (199)

1. Cruz, M., R. Jenkins, and D. Silberberg, The Burden of Brain Disorders. Science. 2006; 312(5770): 53.
2. DeLegge, M.H. and A. Smoke, Neurodegeneration and inflammation. Nutr Clin Pract. 2008; 23(1): 35-41.
3. Martin, L.J. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res Bull. 1998; 46(4): 281-309.
4. Collier, T.J., N.M. Kanaan, J.H. Kordower. Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011; 12(6): 359-366.
5. Tollervey, J.R. Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Research, 2011.
6. Amor, S. Inflammation in neurodegenerative diseases. Immunology. 2010; 129(2): 154-169.
7. Lucas, S.M., N.J. Rothwell, R.M. Gibson, The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006; 147 Suppl 1: S232-40.
8. Bramlett, H.M. and W.D. Dietrich. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab. 2004; 24(2): 133-50.
9. Sugama, S. Stress-induced microglial activation may facilitate the progression of neurodegenerative disorders. Medical Hypotheses. 2009; 73(6): 1031-1034.
10. Butterfield, R.J. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol. 2000; 157(2): 637-45.
11. Elbaz, A., C. Dufouil, and A. Alpérovitch. Interaction between genes and environment in neurodegenerative diseases. Comptes Rendus Biologies. 2007; 330(4): 318-328.
12. Campbell, A. Inflammation, neurodegenerative diseases, and environmental exposures. Ann N Y Acad Sci. 2004; 1035: 117-32.
13. Peterson, L.K. and R.S. Fujinami. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007; 184(1-2): 37-44.
14. Hickey, W.F. and H. Kimura. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988; 239(4837): 290-2.
15. Neumann, H. Control of glial immune function by neurons. Glia. 2001; 36(2): 191-9.
16. Kivisäkk, P. Localizing central nervous system immune surveillance: Meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Annals of Neurology. 2009; 65(4): 457-469.
17. Block, M.L. and J.-S. Hong. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Progress in Neurobiology. 2005; 76(2): 77-98.
18. Lassmann, H. and H.M. Wisniewski. Chronic relapsing EAE time course of neurological symptoms and pathology. Acta Neuropathologica. 1978; 43(1): 35-42.
19. Engelhardt, B. and H. Wolburg. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol. 2004; 34(11): 2955-63.
20. Kivisäkk, P. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clinical & Experimental Immunology. 2002; 129(3): 510-518.
21. Reboldi, A. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009; 10(5): 514-523.
22. Engelhardt, B. T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. Clinical and Experimental Neuroimmunology. 2010; 1(2): 79-93.
23. Goverman, J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009; 9(6): 393-407.
24. Piccio, L. Molecular Mechanisms Involved in Lymphocyte Recruitment in Inflamed Brain Microvessels: Critical Roles for P-Selectin Glycoprotein Ligand-1 and Heterotrimeric Gi-Linked Receptors. The Journal of Immunology. 2002; 168(4): 1940-1949.
25. Ransohoff, R.M., P. Kivisakk, and G. Kidd. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003; 3(7): 569-81.
26. Kerschensteiner, M., E. Meinl, and R. Hohlfeld. Neuro-immune crosstalk in CNS diseases. Neuroscience. 2009; 158(3): 1122-32.
27. Isik, A.T. Late onset Alzheimer’s disease in older people. Clin Interv Aging. 2010; 5: 307-11.
28. Mattson, M.P. Pathways towards and away from Alzheimer’s disease. Nature. 2004; 430(7000): 631-639.
29. Jalbert, J.J., L.A. Daiello, and K.L. Lapane. Dementia of the Alzheimer Type. Epidemiologic Reviews. 2008; 30(1): 15-34.
30. Krause, D.L. and N. Muller. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease. Int J Alzheimers Dis. 2010.
31. Alzheimer’s-Association, 2011 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia. 2011; 7(2): 208-244.
32. Ang, E.T. Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration. Front Aging Neurosci. 2010: 2.
33. Ballatore, C., V.M.Y. Lee, and J.Q. Trojanowski. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007; 8(9): 663-672.
34. Iqbal, K. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010; 7(8): 656-64.
35. Akiyama, H. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000; 21(3): 383-421.
36. Tahara, K. Role of toll-like receptor signalling in Aβ uptake and clearance. Brain. 2006; 129(11): 3006-3019.
37. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12(9): 1005-1015.
38. Griffin, W.S.T. Glial-Neuronal Interactions in Alzheimer’s Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression. Brain Pathology. 1998; 8(1): 65-72.
39. Streit, W.J., S.A. Walter, and N.A. Pennell. Reactive microgliosis. Prog Neurobiol. 1999; 57(6): 563-81.
40. Banati, R.B. Cytotoxicity of microglia. Glia. 1993; 7(1): 111-118.
41. Dickson, D.W. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993; 7(1): 75-83.
42. Wyss-Coray, T. TGF-[beta]1 promotes microglial amyloid-[beta] clearance and reduces plaque burden in transgenic mice. Nat Med. 2001; 7(5): 612-618.
43. Mrak, R.E., J.G. Sheng, and W.S. Griffin. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol. 1996; 55(3): 273-9.
44. Del Bo, R. Reciprocal control of inflammatory cytokines, IL-1 and IL- 6, and [beta]-amyloid production in cultures. Neuroscience Letters. 1995; 188(1): 70-74.
45. Hampel, H. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer’s disease brain. European Archives of Psychiatry and Clinical Neuroscience. 2005; 255(4): 269-278.
46. Flanders, K.C., R.F. Ren, and C.F. Lippa. TRANSFORMING GROWTH FACTOR-[beta]S IN NEURODEGENERATIVE DISEASE. Progress in Neurobiology. 1998; 54(1): 71-85.
47. Akiyama, H. Expression of intercellular adhesion molecule (ICAM)- 1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathologica. 1993; 85(6): 628-634.
48. Hirst, W.D. Expression of COX-2 by Normal and Reactive Astrocytes in the Adult Rat Central Nervous System. Molecular and Cellular Neuroscience. 1999; 13(1): 57-68.
49. DeWitt, D.A. Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer’s Disease. Experimental Neurology. 1998; 149(2): 329-340.
50. Lue, L.F., et al. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol. 1996. 55(10): 1083-8.
51. Webster, S., et al. Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease. Neurobiology of Aging. 1997; 18(4): 415-421.
52. Togo, T., et al. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. Journal of Neuroimmunology. 2002;124(1-2): 83-92.
53. Saresella, M. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer’s disease. Brain, Behavior, and Immunity. 2011 25(3): 539-547.
54. Saresella, M. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2010; 21(3): 927-38.
55. Bö, L., et al. Grey matter pathology in multiple sclerosis. Acta Neurologica Scandinavica. 2006; 113: 48-50.
56. McFarland, H.F. and R. Martin. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007; 8(9): 913-9.
57. van Horssen, J., et al. Radical changes in multiple sclerosis pathogenesis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2011; 1812(2): 141-150.
58. Tienari, P.J. Multiple Sclerosis: Multiple Etiologies, Multiple Genes? Annals of Medicine. 1994; 26(4): 259-269.
59. Hafler, D.A. Multiple sclerosis. The Journal of Clinical Investigation. 2004; 113(6): 788-794.
60. Noseworthy, J.H. Multiple Sclerosis. New England Journal of Medicine. 2000; 343(13): 938-952.
61. Bö, L. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol. 2003; 62(7): 723-32.
62. Frohman, E.M., M.K. Racke, and C.S. Raine. Multiple Sclerosis — The Plaque and Its Pathogenesis. New England Journal of Medicine. 2006;354(9): 942-955.
63. The_International_Multiple_Sclerosis_Genetics_Consortium and The_Wellcome_Trust_Case_Control_Consortium_2, Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359): 214-219.
64. Handel, A.E. Smoking and Multiple Sclerosis: An Updated Meta- Analysis. PLoS ONE. 2011; 6(1): 16149.
65. Munger, K.L. Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis. JAMA The Journal of the American Medical Association. 2006; 296(23): 2832-2838.
66. Sundström, P. An altered immune response to Epstein-Barr virus in multiple sclerosis. Neurology. 2004; 62(12): 2277-2282.
67. Thacker, E.L., F. Mirzaei, and A. Ascherio. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Annals of Neurology. 2006; 59(3): 499-503.
68. O’Connor, K.C., A. Bar-Or, and D.A. Hafler. The Neuroimmunology of Multiple Sclerosis: Possible Roles of T and B Lymphocytes in Immunopathogenesis. Journal of Clinical Immunology. 2001; 21(2): 81-92.
69. Comabella, M. and S.J. Khoury. Immunopathogenesis of multiple sclerosis. Clinical Immunology. 2011: In Press, Corrected Proof.
70. Diaz-Villoslada, P. Autoreactivity to myelin antigens: myelin/ oligodendrocyte glycoprotein is a prevalent autoantigen. Journal of Neuroimmunology. 1999; 99(1): 36-43.
71. Lovett-Racke, A.E. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. The Journal of Clinical Investigation. 1998; 101(4): 725-730.
72. Babbe, H. Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. The Journal of Experimental Medicine. 2000; 192(3): 393-404.
73. Mosmann, T.R. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. The Journal of Immunology. 1986; 136(7): 2348-2357.
74. Panitch, H.S. Treatment of multiple sclerosis with gamma interferon. Neurology. 1987; 37(7): 1097.
75. Lassmann, H. and R.M. Ransohoff. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends in Immunology. 2004; 25(3): 132-137.
76. Brucklacher-Waldert, V. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009; 132(12): 3329-3341.
77. Viglietta, V. Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis. The Journal of Experimental Medicine. 2004; 199(7): 971-979.
78. Neumann, H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002; 25(6): 313-9.
79. Forno, L.S. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol. 1996; 55(3): 259-72.
80. Olanow, C.W. and W.G. Tatton. ETIOLOGY AND PATHOGENESIS OF PARKINSON’S DISEASE. Annual Review of Neuroscience. 1999; 22(1): 123-144.
81. Irvine, G.B. Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med. 2008; 14(7-8): 451-64.
82. Obeso, J.A. Missing pieces in the Parkinson’s disease puzzle. Nat Med. 2010; 16(6): 653-661.
83. Koller, W. Environmental risk factors in Parkinson’s disease. Neurology. 1990; 40(8): 1218-21.
84. Tanner, C.M. and J.W. Langston. Do environmental toxins cause Parkinson’s disease? A critical review. Neurology. 1990; 40(10 Suppl 3): suppl 17-31.
85. Golbe, L.I. The genetics of Parkinson’s disease: a reconsideration. Neurology. 1990; 40(10 Suppl 3): 7-14, 14-6.
86. Hunot, S. and E.C. Hirsch. Neuroinflammatory processes in Parkinson’s disease. Annals of Neurology. 2003; 53(S3): S49-S60.
87. Imamura, K. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathologica. 2003; 106(6): 518-526.
88. Lee, J.-K., T. Tran, and M. Tansey. Neuroinflammation in Parkinson’s Disease. Journal of Neuroimmune Pharmacology. 2009; 4(4): 419-429.
89. McGeer, P.L. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8): 1285-91.
90. Kurkowska-Jastrzebska, I. The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse. Experimental Neurology. 1999; 156(1): 50-61.
91. Ransohoff, R.M. and V.H. Perry. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009; 27: 119-45.
92. Le, W.-d., et al. Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson’s Disease. The Journal of Neuroscience. 2001;21(21): 8447-8455.
93. Ciesielska, A. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson’s disease. Acta Neurobiol Exp (Wars). 2003; 63(2): 117-26.
94. Griffin, W.S. Interleukin-1 mediates Alzheimer and Lewy body pathologies. Journal of Neuroinflammation. 2006; 3(1): 5.
95. Knott, C., G. Stern, and G.P. Wilkin. Inflammatory Regulators in Parkinson’s Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2. Molecular and Cellular Neuroscience. 2000; 16(6): 724-739.
96. McGeer, E.G., A. Klegeris, and P.L. McGeer. Inflammation, the complement system and the diseases of aging. Neurobiology of Aging. 2005; 26(1, Supplement): 94-97.
97. Klegeris, A. [alpha]-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiology of Aging. 2008; 29(5): 739-752.
98. McGeer, P.L. and E.G. McGeer. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism & Related Disorders. 2004; 10(Supplement 1): p. S3-S7.
99. Liberatore, G.T. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999; 5(12): 1403-1409.
100. Engelhardt, B. Immune cell entry into the central nervous system: Involvement of adhesion molecules and chemokines. Journal of the Neurological Sciences. 2008; 274(1-2): 23-26.
101. Brochard, V. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009; 119(1): 182-92.
102. Chung, Y.C. The role of neuroinflammation on the pathogenesis of Parkinson’s disease. BMB Rep. 2010; 43(4): 225-32.
103. Huang, X. CD 4+ T cells in the pathobiology of neurodegenerative disorders. Journal of Neuroimmunology. 2009; 211(1-2): 3-15.
104. Rezai-Zadeh, K., D. Gate, and T. Town. CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease? Journal of Neuroimmune Pharmacology. 2009; 4(4): 462-475.
105. Reynolds, A.D. Regulatory T Cells Attenuate Th17 Cell- Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease. The Journal of Immunology. 2010; 184(5): 2261-2271.
106. Reynolds, A.D. Nitrated alpha-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets. The Journal of Immunology. 2009. 182(7): 4137-4149.
107. Reynolds, A.D. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of ParkinsonÂ’s disease. Journal of Leukocyte Biology. 2007; 82(5):1083-1094.
108. Warlow, C. Stroke. The Lancet. 2003; 362(9391): 1211-1224.
109. Donnan, G.A. Stroke. The Lancet. 2008; 371(9624): 1612-1623.
110. Auer, R.N. and G.R. Sutherland. Primary intracerebral hemorrhage: pathophysiology. Can J Neurol Sci. 2005; 32 Suppl 2: S3-12.
111. Flynn, R.W.V., R.S.M. MacWalter, and A.S.F. Doney. The cost of cerebral ischaemia. Neuropharmacology. 2008; 55(3): 250-256.
112. Hossmann, K.A.. Viability thresholds and the penumbra of focal ischemia. Annals of Neurology. 1994; 36(4): 557-565.
113. Brouns, R. and P.P. De Deyn. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009; 111(6): 483-95.
114. Sims, N.R. and H. Muyderman. Mitochondria, oxidative metabolism and cell death in stroke. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2010; 1802(1): 80-91.
115. Denes, A. Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. Brain, Behavior, and Immunity. 2010; 24(5): 708-723.
116. McColl, B.W., S.M. Allan, and N.J. Rothwell. Systemic inflammation and stroke: aetiology, pathology and targets for therapy. Biochem Soc Trans. 2007; 35(Pt 5): 1163-5.
117. McColl, B.W., S.M. Allan, and N.J. Rothwell. Systemic infection, inflammation and acute ischemic stroke. Neuroscience. 2009. 158(3): p. 1049-1061.
118. Wang, Q., X.N. Tang, and M.A. Yenari, The inflammatory response in stroke. J Neuroimmunol. 2007; 184(1-2): 53-68.
119. Katsura, K., T. Kristian, and B.K. Siesjo. Energy metabolism, ion homeostasis, and cell damage in the brain. Biochem Soc Trans. 1994; 22(4): 991-6.
120. Martin, R.L., H.G.E. Lloyd, and A.I. Cowan. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? Trends in neurosciences. 1994; 17(6): 251-257.
121. Nicholls, D. and D. Attwell. The release and uptake of excitatory amino acids. Trends in Pharmacological Sciences. 1990; 11(11): 462-468.
122. Choi, D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends in neurosciences. 1988; 11(10): 465-469.
123. Meldrum, B. ISCHAEMIC BRAIN DAMAGE: THE ROLE OF EXCITATORY ACTIVITY AND OF CALCIUM ENTRY. British Journal of Anaesthesia. 1985; 57(1): 44-46.
124. Rothman, S.M. and J.W. Olney. Glutamate and the pathophysiology of hypoxic–ischemic brain damage. Annals of Neurology. 1986. 19(2): 105-111.
125. Coyle, J.T. and P. Puttfarcken. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993; 262(5134):689-95.
126. Langley, B. and R.R. Ratan. Oxidative stress-induced death in the nervous system: Cell cycle dependent or independent? Journal of Neuroscience Research. 2004; 77(5): 621-629.
127. Chan, P.H. Reactive Oxygen Radicals in Signaling and Damage in the Ischemic Brain. J Cereb Blood Flow Metab. 2001; 21(1): 2-14.
128. Love, S. Oxidative Stress in Brain Ischemia. Brain Pathology. 1999; 9(1): p. 119-131.
129. Nelson, C.W. Oxygen radicals in cerebral ischemia. American Journal of Physiology - Heart and Circulatory Physiology. 1992; 263(5): H1356-H1362.
130. Dong, Y. and E.N. Benveniste. Immune function of astrocytes. Glia. 2001; 36(2): 180-190.
131. Morioka, T., A.N. Kalehua, and W.J. Streit. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. The Journal of Comparative Neurology. 1993; 327(1): 123-132.
132. Liu, T. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke. 1993; 24(11): 1746-1750.
133. Minami, M. Induction of Interleukin-1β mRNA in Rat Brain After Transient Forebrain Ischemia. Journal of Neurochemistry. 1992; 58(1): 390-392.
134. Brough, D., P.J. Tyrrell, and S.M. Allan. Regulation of interleukin-1 in acute brain injury. Trends in Pharmacological Sciences. 2011; 32(10): 617-622.
135. Yan, J. Immune activation in the peripheral blood of patients with acute ischemic stroke. Journal of Neuroimmunology. 2009; 206(1-2):112-117.
136. Offner, H. Splenic Atrophy in Experimental Stroke Is Accompanied by Increased Regulatory T Cells and Circulating Macrophages. The Journal of Immunology. 2006. 176(11): 6523-6531.
137. Blann, A.D., P.M. Ridker, and G.Y.H. Lip. Inflammation, Cell Adhesion Molecules, and Stroke: Tools in Pathophysiology and Epidemiology? Stroke. 2002; 33(9): 2141-2143.
138. Engelhardt, B., F.K. Conley, and E.C. Butcher. Cell adhesion molecules on vessels during inflammation in the mouse central nervous system. Journal of Neuroimmunology. 1994; 51(2): 199-208.
139. Stoll, G., S. Jander, and M. Schroeter. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol. 1998; 56(2): 149-71.
140. Tanne, D. Soluble Intercellular Adhesion Molecule-1 and Risk of Future Ischemic Stroke. Stroke. 2002; 33(9): 2182-2186.
141. Fumagalli, S. In Vivo Real-Time Multiphoton Imaging of T Lymphocytes in the Mouse Brain After Experimental Stroke. Stroke. 2011; 42(5): 1429-1436.
142. Gee, J.M. Lymphocytes: Potential Mediators of Postischemic Injury and Neuroprotection. Stroke, 2007. 38(2): p. 783-788.
143. Ortolano, F. Advances in imaging of new targets for pharmacological intervention in stroke: real-time tracking of T-cells in the ischaemic brain. British Journal of Pharmacology. 2010; 159(4): 808-811.
144. Schroeter, M. Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. Journal of Neuroimmunology. 1994; 55(2): 195-203.
145. Hurn, P.D. T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab. 2007; 27(11): 1798-1805.
146. Liesz, A. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain. 2011; 134(3): 704-720.
147. Frenkel, D. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci. 2005; 233(1-2): 125-32.
148. Planas, A.M. and A. Chamorro. Regulatory T cells protect the brain after stroke. Nat Med. 2009; 15(2): 138-139.
149. Ren, X. Regulatory B Cells Limit CNS Inflammation and Neurologic Deficits in Murine Experimental Stroke. The Journal of Neuroscience. 2011; 31(23): 8556-8563.
150. Engelhardt, B., Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm. 2006; 113(4): 477-85.
151. Engelhardt, B. and R.M. Ransohoff. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005; 26(9): 485-95.
152. Fee, D. Activated/effector CD4+ T cells exacerbate acute damage in the central nervous system following traumatic injury. J Neuroimmunol. 2003; 136(1-2): 54-66.
153. Appel, S.H. CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest. 2009; 119(1): 13-5.
154. Popovich, P.G., P. Wei, and B.T. Stokes. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997; 377(3): 443-64.
155. Popovich, P.G., B.T. Stokes, and C.C. Whitacre. Concept of autoimmunity following spinal cord injury: Possible roles for T lymphocytes in the traumatized central nervous system. Journal of Neuroscience Research. 1996; 45(4): 349-363.
156. Wang, W.Z. Myelin antigen reactive T cells in cerebrovascular diseases. Clinical & Experimental Immunology. 1992; 88(1): 157-162.
157. Olsson, T. Autoreactive T and B cell responses to myelin antigens after diagnostic sural nerve biopsy. Journal of the Neurological Sciences. 1993; 117(1-2): 130-139.
158. Kil, K. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. Journal of Neuroimmunology. 1999; 98(2): 201-207.
159. Viviani, B. Cytokines role in neurodegenerative events. Toxicol Lett. 2004; 149(1-3): 85-9.
160. Hsu, H. TRADD TRAF2 and TRADD FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways. Cell. 1996. 84(2): 299-308.
161. Mogi, M. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. Journal of Neural Transmission. 2000; 107(3): 335-341.
162. Dittel, B.N. Evidence that Fas and FasL contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz). 2000. 48(5): 381-8.
163. Nagata, S. and T. Suda, Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995; 16(1): 39-43.
164. Nagata, S. and P. Golstein. The Fas death factor. Science. 1995; 267(5203): 1449-1456.
165. Sabelko-Downes, K.A., A.H. Cross, and J.H. Russell. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med. 1999; 189(8): 1195-205.
166. Medana, I. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol. 2001; 159(3): 809-15.
167. Medana, I.M. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. European Journal of Immunology. 2000; 30(12): 3623-3633.
168. Neumann, H. Induction of MHC class I genes in neurons. Science. 1995; 269(5223): 549-552.
169. Rensing-Ehl, A. Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. European Journal of Immunology. 1996; 26(9): 2271-2274.
170. Giuliani, F. Vulnerability of Human Neurons to T Cell-Mediated Cytotoxicity. The Journal of Immunology. 2003; 171(1): 368-379.
171. Beers, D.R. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proceedings of the National Academy of Sciences. 2008; 105(40): 15558-15563.
172. Moalem, G. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun. 2000; 15(3): 331-45.
173. Moalem, G. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999; 5(1): 49-55.
174. Schwartz, M. T-cell-based vaccination against neurodegeneration: a new therapeutic approach. Retina. 2005; 25(8 Suppl):S33-S35.
175. Wolf, S.A. Neuroprotection by T-cells depends on their subtype and activation state. J Neuroimmunol. 2002; 133(1-2): 72-80.
176. Serpe, C.J. CD4+ T, but not CD8+ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain, Behavior, and Immunity. 2003; 17(5):393-402.
177. Serpe, C.J. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci. 1999; 19(11): RC7.
178. Hauben, E. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci. 2000; 20(17): 6421-30.
179. Hauben, E. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 2000; 355(9200): 286-7.
180. Gimsa, U. Th2 cells support intrinsic anti-inflammatory properties of the brain. Journal of Neuroimmunology. 2001; 119(1): 73-80.
181. Bettelli, E. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090): 235-8.
182. Chen, W. Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. The Journal of Experimental Medicine. 2003; 198(12): 1875-1886.
183. Nakamura, K., A. Kitani, and W. Strober. Cell Contact-Dependent Immunosuppression by Cd4++Cd25+Regulatory T Cells Is Mediated by Cell Surface-Bound Transforming Growth Factor-beta. The Journal of Experimental Medicine. 2001; 194(5): 629-644.
184. Liu, Y. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med. 2006; 12(5):518-25.
185. Liu, J. Neuromodulatory Activities of CD4+CD25+ Regulatory T Cells in a Murine Model of HIV-1-Associated Neurodegeneration. J Immunol. 2009; 182(6): 3855-3865.
186. Weiner, H.L. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunological Reviews 2001; 182(1): 207-214.
187. Xin, J. IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection. Brain, Behavior, and Immunity. 2011; 25(5): 820-829.
188. Hammarberg, H. Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells. The Journal of Neuroscience. 2000; 20(14): 5283-5291.
189. Shaked, I. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem. 2005; 92(5): 997-1009.
190. Hjelmström, P. Cutting Edge: B Cell-Deficient Mice Develop Experimental Allergic Encephalomyelitis with Demyelination After Myelin Oligodendrocyte Glycoprotein Sensitization. The Journal of Immunology. 1998; 161(9): 4480-4483.
191. Wolf, S.D. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996; 184(6): 2271-8.
192. Matsushita, T. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol. 2006; 168(3): 812-21.
193. Matsushita, T. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008; 118(10): 3420-30.
194. Fillatreau, S. B cells regulate autoimmunity by provision of IL- 10. Nat Immunol. 2002; 3(10): 944-950.
195. Lyons, J.-A. B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice. Journal of Autoimmunity. 2008; 31(2): 149-155.
196. Edling, A.E. Human and murine lymphocyte neurotrophin expression is confined to B cells. J Neurosci Res. 2004; 77(5): 709-17.
197. Kala, M. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010; 221(1): 136-45.
198. Kerschensteiner M. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999; 189(5): 865-70.
199. Shrestha R, O. Millington J Brewer, K K Dev and T. J. Bushell (2014). “Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways.” Neuropharmacology. 76 Pt A: 184-193.